Navigation Links
Vanda Presents Phase III Iloperidone Efficacy Data
Date:12/12/2007

Findings also demonstrate favorable safety and tolerability profile

ROCKVILLE, Md., Dec. 12 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that data from four Phase III efficacy and safety trials demonstrate that iloperidone, an investigational atypical antipsychotic, is associated with significantly greater improvements in the symptoms of schizophrenia versus placebo and has a favorable safety and tolerability profile. These results were included as part of the recently filed New Drug Application (NDA) for iloperidone and were presented for the first time this week at a major psychiatric congress. Posters containing the data presented will be posted on Vanda's Web site, http://www.vandapharma.com, on Thursday, December 13, 2007. The U.S. Food and Drug Administration (FDA) accepted the NDA submitted by Vanda for marketing approval on November 26, 2007.

The Phase III study conducted by Vanda evaluated the efficacy of iloperidone versus placebo in patients with schizophrenia. The study was a randomized, double-blind, placebo-controlled, multi-center, four-week inpatient study that enrolled 604 patients. Following fixed-dose titration, inpatients were randomized to receive iloperidone at 24 mg/day, ziprasidone at 160 mg/day, or placebo. Patients treated with iloperidone had significantly greater improvements in Positive and Negative Syndrome Scale-Total (PANSS-T) scores than those on placebo and had PANSS-T improvement comparable to ziprasidone.

"There is a great need for new treatment options for schizophrenia, particularly as patients often discontinue treatment due to efficacy and tolerability issues, as seen in the NIMH-funded
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... CHAPEL HILL, N.C. , June 18, 2013 /PRNewswire/ ... and more difficult for Medical Education groups at large ... practitioners on the safe and effective use of their ... within the pharma industry, it is crucial that these ... of reaching healthcare professionals. To address the ...
(Date:6/18/2013)...  Cataracts are the leading cause of blindness in ... aging is the leading cause of eye diseases such ... 22 million Americans age 40 and older have cataracts, ... that number will increase over 30 million.  In a ... and computers, the demographic of ages 40 plus works ...
(Date:6/18/2013)... -- In a letter to authorities at her hospital, orthopaedic surgeon ... View, Iowa , writes that a policy of forcing ... scientifically justified nor ethically sound. Her letter is ... of the Journal of American Physicians and Surgeons. ... average of 36,000 patients per year die in U.S. hospitals ...
Breaking Medicine Technology:Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2New Vision Hope For Millions Undergoing Cataract Surgery 2New Vision Hope For Millions Undergoing Cataract Surgery 3Mandated Flu Vaccine for Hospital Workers Ethically Questionable, Surgeon Writes 2
(Date:6/18/2013)... Consumer injury attorney Michael J. Evans announced ... launched a new website for people who believe they ... is http://www.DialysisLawsuitAttorneys.com . , "My litigation partners and ... services to people who may have been injured by ... may have suffered injuries due to some other form ...
(Date:6/18/2013)... 2013 "What if adding one simple ... boost your health and well-being? Well, there is something ... Beauty®. "It is called Skin Brushing ." , ... a lost art. Now, people are rediscovering this great ... and so do certain health conscious people. Sublime Beauty® ...
(Date:6/18/2013)... 2013 Looking for a way to break ... life? , IWALKAWAKE is a guide to unlocking one’s ... Botha, it focuses on harnessing the powerful and abundant spiritual ... out a nine-step guide to finding one’s true purpose and ... must go through to reach their true potential. The awakenings ...
(Date:6/18/2013)... SEATTLE, WA—A Washington state resident filed ... claiming he fell ill with a hepatitis A infection ... blend. The complaint was filed in Snohomish County ... Seattle-based law firm that has filed 14 previous ... complaint, Brian Brothers consumed “Townsend Farms Organic Antioxidant Blend” ...
(Date:6/18/2013)... Horsham, PA (PRWEB) June 18, 2013 Senior ... in Boston on June 25 to discuss—for the first time ... agencies in getting drugs through the regulatory process in a ... of drug evaluation will share respective best practices and processes ... Across the Strait panel at the DIA 2013 ...
Breaking Medicine News(10 mins):Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 2Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 3Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 4Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 3Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2
... A growing number of Americans know about chronic obstructive pulmonary ... disease, a new survey has found. According to the ... knew about COPD, a 4 percent increase from 2008. Awareness ... results were released this week by the U.S. National Heart, ...
... (Geneva, Switzerland) A Pneumonia Report Card released today ... of the Global Coalition against Child Pneumonia reveals where ... coverage for the life-saving interventions that can prevent, protect ... is the world,s leading infectious killer of young children, ...
... A new study from researchers in Colorado shows that women ... a screening colonoscopy than those who were not offered this ... to be common among women. In this study, a patient ... screening colonoscopy can be increased by offering women the option ...
... 11, 2010 The November 2010 issue of the ... Journal of the American Congress of Rehabilitation Medicine, has ... injury (TBI) that will accelerate future research in the ... injury, how it is measured and classified, treatment and ...
... 11 (HealthDay News) -- Diabetes is a leading cause of ... the risk factors and what they can do to prevent ... "Diabetes is a chronic condition that can cause serious ... kidney failure and nervous system damage," ACP President Dr. J. ...
... release is available in French . , Montreal, ... should receive an additional cardiac test when undergoing diagnosis for ... University, the Universit du Qubec Montral and the Montreal ... in the Journal of Cardiopulmonary Rehabilitation and Prevention , ...
Cached Medicine News:Health News:Awareness of COPD Growing, But More Lung Testing Urged 2Health News:Efforts to combat pneumonia among 15 high-burdened countries fall short of recommended targets 2Health News:Efforts to combat pneumonia among 15 high-burdened countries fall short of recommended targets 3Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 2Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 3Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 4Health News:Consensus on TBI and PTSD will accelerate future research and improve patient care 2Health News:Consensus on TBI and PTSD will accelerate future research and improve patient care 3Health News:Consensus on TBI and PTSD will accelerate future research and improve patient care 4Health News:Consensus on TBI and PTSD will accelerate future research and improve patient care 5Health News:Consensus on TBI and PTSD will accelerate future research and improve patient care 6Health News:Are You at Risk of Developing Diabetes? 2Health News:Additional cardiac testing vital for patients with anxiety and depression 2
Directional `E' and `C' test....
9" X 14" translucent plastic may be used with illuminated test cabinet or as a wall chart 20/200 to 20/15....
... The PowerLab/16SP is a high-performance recording unit ... science research applications that require up to ... and isolated tissue studies. The unit is ... to 200 000 samples per second continuously ...
Three Figure Worth Type Test, this test is used for determining diplopia, suppression or fusion in children. Sturdy chrome flashlight comes with red/green glasses. Requires 3 D batteries which are no...
Medicine Products: